Home
6494 All Specialties
1559 Arthroplasty
641 Shoulder & Elbow
577 Osteoarthritis
575 Physical Therapy & Rehab
570 Spine
552 Sports Medicine
543 Trauma
412 General Orthopaedics
345 Foot & Ankle
295 Hand & Wrist
198 Cannabis
88 Pediatric Orthopaedics
79 Metabolic Disorders
29 Peri-Operative
29 Tumour
2 Evidence Based Medicine

Conference Reports

Summaries of the best evidence presented at major orthopaedic conferences around the world.

Exclusive Interviews

Original authors are interviewed to verify the veracity of the ACE Report and provide additional information regarding the study’s findings and methodology.

PeerView

Features the top trending OE Content from your network over the past 30 days.

OE Originals
OE Insights
Videos
OE Plus
148 COVID 19 Resource Center
7 Ace Reviews
1 OE Recommends
6 OE PeerView
78 OE Ideas
24 OE World Tour
63 OE Perspectives
48 Conference ACE Reports
159 Exclusive Interviews
CME

To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Vol:6 Issue:1 Number:23 ISSN#:2564-2537
DOWNLOAD ESPAÑOL
Author Verified
RCT
ACE Report #9177
Ace Report Cover Metabolic Disorders

Combination therapy improves site-specific BMD vs. teriparatide & denosumab monotherapies

How to Cite

OrthoEvidence. Combination therapy improves site-specific BMD vs. teriparatide & denosumab monotherapies. ACE Report. 2017;6(1):23. Available from: https://myorthoevidence.com/AceReport/Report/9177

Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Response to Therapy With Teriparatide, Denosumab, or Both in Postmenopausal Women in the DATA (Denosumab and Teriparatide Administration) Study Randomized Controlled Trial

J Clin Densitom. 2016 Jul-Sep;19(3):346-51

Contributing Authors:
BZ Leder JN Tsai RM Neer AV Uihlein PM Wallace SA Burnett-Bowie

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

94 postmenopausal osteoporotic women were randomized to receive either 60mg denosumab subcutaneously every 6 months, 20ug teriparatide subcutaneously daily, or a combination treatment of both 60mg denosumab and 20ug teriparatide for a duration of 24 months. The purpose of this study was to compare the individual response rates of the three treatment groups in terms of increases in bone mineral den...

To view the full content, login to your account,
or start your 30-day FREE Trial today.

FREE TRIAL Forgot Password?

Explore some of our unlocked ACE Reports below!

 Zoledronic acid increases BMD and prevents fracture risks in women with osteoporosis
Effects of 2.5mg zoledronate are long-lasting and similar to 5mg dose in osteopenic women
Network meta-analysis of current drug options for the treatment of osteoporosis in men
Immediate effects on bone metabolism biomarkers noted with resistance training and walking
Ace Report Preview Image
CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE
For Reprints and Permissions, click here

Please Login or Join to leave comments.